A pharmaceutical composition comprising at least one compound of general formula R 1 -S-CH 2 -OXA-R 2 including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable cocrystals or salts, and complexes thereof; and at least one further active component selected from the group consisting of one or more agonists of GPR40 and/or GPR120, one or more biduanides, one or more DPP-4 inhibitors, one or more α-glucosidase inhibitors, one or more sulfonylurea compounds, one or more glinides, one or more GLP-1 receptor agonists, one or more glucokinase modulators, one or more thiozolidinediones, one or more incretin mimetics, insulin, one or more insulin derivatives and Pramlintide; and at least one pharmaceutical carrier; wherein the at least one compound of general formula is further characterized in that OXA is selected from the group consisting of 1,3-oxazolyl, 1,2,4-oxadiazolyl or 1,3,4-oxadiazolyl; when OXA is 1,3-oxazolyl, the group R 1 -S-CH 2 is bound to C 2 of the 1,3-oxazolyl and the group R 2 is bound to C 4 of the 1,3-oxazolyl; when OXA is 1,2,4-oxadiazolyl the group R 1 -S-CH 2 is bound to C 5 of the 1,2,4-oxadiazolyl and the group R 2 is bound to C 3 of the 1,2,4-oxadiazolyl; when OXA is 1,3,4-oxadiazolyl the group R 1 -S-CH 2 is bound to C 5 of the 1,3,4-oxadiazolyl and the group R 2 is bound to C 2 of the 1,3,4-oxadiazolyl; R 1 is a 6 membered heteroaryl group selected from the group consisting of 1,3,5-triazinyl and pyrimidinyl being independently substituted with one or more substituents selected from the group consisting of hydroxyl, amino, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkoxy, N-mono- or N,N-di-substituted C 1 -C 3 -alkylamino, non-aromatic 5- to 6-membered heterocyclyl, 6-membered aryl and 5- to 6-membered heteroaryl which substituents may be unsubstituted or substituted with one or more groups selected from the group consisting of halide, cyano and C 1 -C 6 -alkyl, wherein the 6-membered aryl and 5- to 6-membered heteroaryl group, respectively, may be fused to said 1,3,5-triazinyl or pyrimidyl group, respectively, and R 2 is phenyl being unsubstituted or being substituted with one or more substituents selected from the group consisting of halide, cyano, amino, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl which may be optionally substituted with one or more halides, C 1 -C 4 -alkoxy which may optionally substituted with one or more halides, hydroxy-C 1 -C 6 -alkyl, sulfonyl-C 1 -C 6 -alkyl, sulphamidyl-N-C 1 -C6-alkyl and carboxamidyl-N-mono- or -N,N-di-C 1 -C 6 -alkyl; with the proviso that the following compounds are excluded: including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable cocrystals or salts, and complexes thereof; and at least one further active component selected from the group consisting of one or more agonists of GPR40 and/or GPR120, one or more biduanides, one or more DPP-4 inhibitors, one or more α-glucosidase inhibitors, one or more sulfonylurea compounds, one or more glinides, one or more GLP-1 receptor agonists, one or more glucokinase modulators, one or more thiozolidinediones, one or more incretin mimetics, insulin, one or more insulin derivatives and Pramlintide; and at least one pharmaceutical carrier; wherein the at least one compound of general formula is further characterized in that OXA is selected from the group consisting of 1,3-oxazolyl, 1,2,4-oxadiazolyl or 1,3,4-oxadiazolyl; when OXA is 1,3-oxazolyl, the group R 1 -S-CH 2 is bound to C 2 of the 1,3-oxazolyl and the group R 2 is bound to C 4 of the 1,3-oxazolyl; when OXA is 1,2,4-oxadiazolyl the group R 1 -S-CH 2 is bound to C 5 of the 1,2,4-oxadiazolyl and the group R 2 is bound to C 3 of the 1,2,4-oxadiazolyl; when OXA is 1,3,4-oxadiazolyl the group R 1 -S-CH 2 is bound to C 5 of the 1,3,4-oxadiazolyl and the group R 2 is bound to C 2 of the 1,3,4-oxadiazolyl; R 1 is a 6 membered heteroaryl group selected from the group consisting of 1,3,5-triazinyl and pyrimidinyl being independently substituted with one or more substituents selected from the group consisting of hydroxyl, amino, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkoxy, N-mono- or N,N-di-substituted C 1 -C 3 -alkylamino, non-aromatic 5- to 6-membered heterocyclyl, 6-membered aryl and 5- to 6-membered heteroaryl which substituents may be unsubstituted or substituted with one or more groups selected from the group consisting of halide, cyano and C 1 -C 6 -alkyl, wherein the 6-membered aryl and 5- to 6-membered heteroaryl group, respectively, may be fused to said 1,3,5-triazinyl or pyrimidyl group, respectively, and R 2 is phenyl being unsubstituted or being substituted with one or more substituents selected from the group consisting of halide, cyano, amino, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl which may be optionally substituted with one or more halides, C 1 -C 4 -alkoxy which may optionally substituted with one or more halides, hydroxy-C 1 -C 6 -alkyl, sulfonyl-C 1 -C 6 -alkyl, sulphamidyl-N-C 1 -C6-alkyl and carboxamidyl-N-mono- or -N,N-di-C 1 -C 6 -alkyl; with the proviso that the following compounds are excluded: